The Ingredients Arms Race: Taste, Color, Smell & Functional Innovation

By Lloyd D. Le Page, Group Chairman, The Sarnian Group

Day 4 of 7 — Food Tech Investment Series, May 2026

Everyone is watching the branded food companies. The better investment is one layer down.

The ingredients industry — the businesses that supply flavor systems, natural colorants, aroma compounds, texture modifiers, and bioactive functional ingredients to food and beverage manufacturers worldwide — generates returns that finished-product brands rarely achieve. Lower consumer risk, predictable B2B revenue, formidable IP protection, and switching costs that can lock in customer relationships for decades. This is the picks-and-shovels layer of the food revolution, and institutional capital has been systematically underweighting it.

Global ingredient and flavor industry revenues exceeded USD 35 billion in 2024. The compound annual growth rate across the next five years is projected at 5.8%. Those are mature-market numbers for a sector that is genuinely being transformed by biotechnology, regulatory pressure, and changing consumer demand profiles. The combination of defensive characteristics and structural tailwinds is uncommon. It deserves attention.

Natural Colors: The Regulatory Tailwind Is Already Priced In — But the IP Race Is Not

The shift from synthetic to natural colorants is not a trend. It is a regulatory mandate with a clear trajectory, and the companies that have built proprietary natural color portfolios are the beneficiaries.

The FDA's 2023 accelerated review of Red No. 3 — ultimately moving toward prohibition — and California's Food Safety Act (effective 2027) banning six synthetic dyes are the leading edge of a global regulatory wave that is already further advanced in the EU. The European Food Safety Authority has been progressively tightening its position on synthetic azo dyes since 2010. What the US is now beginning, Europe has been executing for fifteen years.

The market response has been to build alternative supply. Chr. Hansen, now merged into Novonesis, holds one of the most comprehensive natural pigment portfolios in the industry — microbially-produced carotenoids, anthocyanins, and beetroot-derived betalains that replace synthetic equivalents at commercial scale. GNT Group runs the EXBERRY platform, which uses fruit, vegetable, and plant concentrates to produce colorants without chemical solvents — a clean-label positioning that commands meaningful premium pricing. Oterra (formerly Chr. Hansen's Color division, now independent) has a comparable plant-derived color portfolio with growing fermentation-derived capabilities.

The more interesting play is further upstream: Phytolon, an Israeli biotech, is producing natural food-grade pigments via yeast fermentation — specifically betalains that are structurally identical to the beet-derived compounds but produced without the agricultural land, water, and supply chain variability of conventional extraction. This is precision fermentation applied to colorants, and it solves the scale and consistency problems that have constrained natural color adoption in industrial food manufacturing. If precision fermentation in colors tracks the cost curves seen in other fermentation-produced ingredients, the economics of natural color transition become significantly more compelling within a five-year window.

The IP moat in natural colors is real: proprietary fermentation strains, extraction processes, and stabilisation technologies are all patentable. The switching cost for a food manufacturer that has reformulated around a specific natural colorant system is high — reformulation requires regulatory notification, consumer panel testing, and shelf-life validation. Once embedded in a product formulation, an ingredient supplier's position is remarkably sticky.

Flavor and Taste Biotech: Engineering the Palate

The global flavors market is valued at approximately USD 18 billion annually and is being restructured by biotechnology from two directions: precision-designed flavor molecules produced via biosynthesis, and sweetness/bitterness modulation proteins that change how the human palate perceives taste.

Conagen, a Massachusetts-based synthetic biology company, has built a fermentation-based production platform for flavor molecules that are structurally identical to their naturally-occurring counterparts — vanillin, raspberry ketone, citrus terpenes — at costs that undercut conventional extraction. The "bio-identical" positioning is significant: these products qualify as "natural flavor" under FDA labeling rules (since they use biological production processes) while delivering the consistency and supply reliability of synthetic production. That regulatory classification unlocks access to the premium natural flavor market without the supply chain constraints of plant extraction.

Sweegen is attacking a different problem: the bitterness aftertaste that limits stevia adoption in high-substitution applications. The company's Bestevia line uses bioconversion to produce rare stevia rebaudiosides — Reb M and Reb D — that have significantly reduced bitterness compared to the more commonly used Reb A. The market size here is substantial: sugar reduction is a USD 100B+ challenge across food and beverage, and the technical failure mode of every high-intensity sweetener has been palatability in high-substitution applications. A sweetener that can replace sugar at 1:1 functionality without bitterness is not a niche product. It is foundational infrastructure for reformulation across categories.

Amai Proteins is working on a further-upstream solution: sweet proteins produced via precision fermentation from naturally-occurring sequences found in rare tropical fruits. Sweet proteins like thaumatin and brazzein are 100,000 times sweeter than sucrose by weight — the challenge has always been production economics and technical functionality. Amai is engineering variants that improve heat stability and solubility while reducing production cost. If functional sweet proteins reach commercial scale before 2030, they represent a structural disruption to the high-intensity sweetener market.

The flavor biotech investment thesis is not about any single molecule. It is about the platform: companies that have built biosynthesis infrastructure capable of producing a portfolio of flavor compounds on demand have a significant cost and speed-to-market advantage over conventional extraction-based suppliers. The R&D pipeline is a portfolio of IP options. The manufacturing platform is the moat.

Aroma Engineering and Encapsulation: The Invisible Performance Layer

Aroma is the dominant contributor to flavor perception — estimates suggest 80% of what humans perceive as "flavor" is actually smell. Yet aroma chemistry in food applications is one of the least discussed areas of ingredients technology.

The technical challenge is stability: aroma compounds are volatile by definition, and the conditions of food manufacturing — heat, pH, oxygen exposure, shear — degrade them. The commercial solution is encapsulation: binding aroma compounds in protective matrices (cyclodextrins, protein-based microcapsules, lipid systems, spray-dried matrices) that release at the right moment — on chewing, on heating, on contact with saliva.

The encapsulation technology layer has become a significant competitive differentiator. Givaudan, the Swiss flavor and fragrance giant with USD 7.2 billion in 2024 revenues, has invested heavily in encapsulation IP. IFF (International Flavors & Fragrances) runs a comparable encapsulation technology program through its taste and wellbeing division. Both companies have made the judgment that aroma delivery technology — not just the aromatic molecules themselves — is a source of differentiation and margin.

The emerging development is microbiome-interactive encapsulation: designing release profiles that interact with the gut microbiome to produce desired secondary metabolites. This sits at the intersection of aroma technology and functional nutrition and represents a genuine next-frontier capability. Several early-stage companies (notably in the Netherlands and Israel, where food science research infrastructure is strong) are pursuing this direction.

Texture Innovation: The Plant-Based Problem Nobody Talks About

The most persistent obstacle to plant-based food adoption is not flavor. It is texture — specifically, mouthfeel: the creaminess, fattiness, and lubrication that animal-derived fats provide and that plant-based formulations have struggled to replicate.

Fat replacers are not new — the category dates to fat-reduced food development in the 1990s. What is new is the precision of the problem statement. Plant-based meat and dairy applications require texture performance that generic fat replacer technology does not deliver. The need is for ingredients that mimic the specific melt profile, mouthcoating, and microstructural behavior of animal fats in complex matrices.

Bunge Loders Croklaan (part of Bunge Limited) and AAK are the established structured fat specialists — companies that blend, fractionate, and enzymatically modify vegetable fats to achieve specific functional profiles. Both are seeing increased demand from plant-based product developers.

The more disruptive development is precision fermentation-derived fats. Several startups — Zero Acre Farms, Yali Bio (formerly Checkerspot) — are producing novel lipid profiles via microbial fermentation. The target is not cost parity with conventional vegetable oils; it is functional performance that conventional plant fats cannot deliver: specific fatty acid compositions, crystallisation behavior, and nutritional profiles. The unit economics are still not at commercial scale, but the directional trajectory is clear.

Hydrocolloid-based texture systems represent the mature end of this market. Methylcellulose (the compound that gives Impossible Burgers their fat-like melt behavior), carrageenan, pectin, gellan gum, and modified starches are well-established, high-margin ingredients with genuine technical defensibility. The companies that supply these — CP Kelco (now part of J.M. Huber), Ingredion, Tate & Lyle — have built substantial technical service infrastructure around formulation support that creates customer lock-in beyond the ingredient itself.

Nutraceuticals and Bioactives: The Functional Food Mainstream

The boundary between food and pharmaceutical is dissolving, and the ingredient companies positioned at that boundary are capturing the value.

The global nutraceuticals ingredients market — bioactive compounds, functional peptides, vitamins, minerals, botanical extracts, probiotics, prebiotics, adaptogens — was valued at USD 85 billion in 2024 and is forecast to exceed USD 140 billion by 2030. That is not a supplement market size; it is a food ingredient market size, because the majority of growth is in fortified food and beverage applications, not standalone supplements.

The trend lines that matter for investors:

Adaptogens entering mainstream. Ashwagandha, rhodiola, reishi, and lion's mane — compounds with documented stress-response modulation effects in peer-reviewed literature — are moving from specialist health food stores into mass-market beverages, snack bars, and functional foods. Ixoreal Biomed (KSM-66 ashwagandha) and Sabinsa Corporation have built proprietary standardised extract IP that commands significant premium over commodity botanical extracts. Standardisation — the ability to guarantee specific bioactive compound concentrations across lots — is the technical moat.

Probiotic and postbiotic ingredients scaling. Chr. Hansen/Novonesis holds the broadest commercial probiotic strain portfolio in the market. DuPont Nutrition & Biosciences (now part of IFF) and Kerry Group have substantial probiotic ingredient businesses. The emerging category is postbiotics — heat-inactivated microbial biomass and fermentation metabolites that provide health benefits without requiring viable organisms, which dramatically simplifies formulation and shelf-life challenges.

Precision nutrition ingredients. The development of AI-assisted formulation tools — startups like Brightseed (using machine learning to map bioactive compound databases from plant sources) and NotCo (using AI for formulation matching) — is accelerating the discovery and validation of novel bioactive compounds. This is a 5–7 year development cycle, but the companies building the bioactive discovery infrastructure are accumulating IP that will be valuable as the functional food category continues to expand.

Why Ingredients Companies Win on Margins

The B2B nature of the ingredients business is its defining financial characteristic.

A flavor or colorant company does not manage retail shelf placement, consumer marketing, or brand equity. It sells to food manufacturers on multi-year supply contracts with technical service components. Customer acquisition is slow and expensive — it involves formulation trials, regulatory sign-off, and manufacturing integration. But once acquired, customers rarely switch. The total cost of substituting an ingredient — reformulation, regulatory notification, consumer panel testing, shelf-life validation, supply chain qualification of a new supplier — often exceeds the theoretical cost savings by a large margin.

The margin profile reflects this. Major ingredients companies — Givaudan (operating margins consistently above 15%), IFF (recovering toward 12–14% post-integration), DSM-Firmenich (combined entity targeting 20%+ EBITDA margins) — operate at margins that consumer food brands cannot sustain. Consumer brands compete on marketing spend, retailer relationships, and consumer sentiment, all of which are volatile. Ingredients companies compete on technical performance, regulatory compliance, and customer service, all of which favor incumbents.

The M&A activity in the sector reflects the value of scale and portfolio breadth. The DSM-Firmenich merger (completed 2023) created a combined entity with EUR 12 billion in revenues that spans vitamins, flavors, enzymes, cultures, and bioactives — a comprehensive ingredients platform with significant cross-selling and R&D leverage. IFF's acquisition of DuPont Nutrition & Biosciences (USD 26.2 billion, 2021) assembled a flavors, textures, probiotics, and food protection portfolio that positioned IFF as a top-three global ingredients company. Novonesis (the combined Chr. Hansen and Novozymes) is the most complete biosolutions platform in the market, covering food cultures, enzymes, probiotic strains, and natural colors under one R&D infrastructure.

The M&A logic is consistent: breadth of formulation capability increases customer stickiness, because a manufacturer who sources flavors, colors, and functional ingredients from the same supplier has substantially higher switching costs than one who sources each category separately.

The Investment Frame: What to Own

The ingredients sector investment case is not complicated. Three positions are worth building:

B2B specialty ingredients with precision fermentation platforms. The companies building microbial production for flavors, colors, and functional compounds are accumulating IP portfolios and production cost advantages that will compound over a 7–10 year horizon. Early-stage investment here requires tolerance for development timelines, but the eventual market positions are defensible.

Established ingredients majors at rational valuations. Post-merger integration challenges at IFF and the broader repricing of specialty chemicals have compressed valuations for some established players. A Givaudan, Novonesis, or IFF at compressed multiples, given the structural defensibility of their customer positions, is a different risk/return than their headline valuations suggest.

Functional and bioactive ingredient specialists. The specific intersection of standardised botanical extracts, postbiotic ingredients, and precision nutrition compounds is growing at above-market rates with formulation-integration moats. Companies like Ixoreal, Sabinsa, and the emerging generation of AI-assisted bioactive discovery startups represent the high-growth end of the ingredients innovation spectrum.

The contrarian framing is this: while institutional capital debates the consumer-facing food and beverage brands — the oat milk leaders, the plant-based burger companies, the functional beverage startups — the ingredient suppliers to all of them are running higher-margin, more defensible businesses with less consumer sentiment risk and better IP protection. Picks and shovels beat the miners in every major resource rush. Food tech is no different.

Tomorrow: the circular economy and waste-to-value layer — where food system inefficiency becomes a commodity stream, and where infrastructure capital is building the processing and logistics needed to monetise it.

Intelligence reports on food technology investment, including premium deal flow analysis, are available at /reports.

Lloyd D. Le Page is Group Chairman of The Sarnian Group, Inc. and founding editor of AgriNexus Intelligence.